Breaking News Instant updates and real-time market news.

MNK

Mallinckrodt

$20.20

0.25 (1.25%)

, MGEN

Miragen Therapeutics

$3.40

-0.12 (-3.41%)

04:55
01/12/19
01/12
04:55
01/12/19
04:55

Jonathan Wood & Associates to hold a forum

11th Annual T-Cell Lymphoma Forum will be held in La Jolla, CA on January 10-12.

MNK

Mallinckrodt

$20.20

0.25 (1.25%)

MGEN

Miragen Therapeutics

$3.40

-0.12 (-3.41%)

SPPI

Spectrum

$11.07

0.195 (1.79%)

  • 18

    Feb

MNK Mallinckrodt
$20.20

0.25 (1.25%)

12/31/18
RILY
12/31/18
NO CHANGE
Target $21
RILY
Neutral
Mallinckrodt price target lowered to $21 from $37 at B. Riley FBR
B. Riley FBR analyst David Buck lowered his price target for Mallinckrodt to $21 after the company earlier this month announced plans to spin off a new company consisting of its specialty generics business and Amitiza to shareholders. The analyst keeps a Neutral rating on the shares.
12/07/18
PIPR
12/07/18
NO CHANGE
Target $39
PIPR
Overweight
Mallinckrodt generics spin-off 'least bad outcome,' says Piper Jaffray
In a research note titled "The Least Bad Outcome for the Generics Business," Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Mallinckrodt with a $39 price target. Given that the generics segment is almost entirely a commodity business, Mallinckrodt not finding a buyer for its active pharmaceutical ingredient and specialty generics businesses is not all that surprising, Amsellem tells investors in a research note. He views yesterday's news of the company announcing a spin-off as the "least bad" outcome. The analyst reiterates an Overweight rating on Mallinckrodt with a $39 price target.
12/07/18
WELS
12/07/18
NO CHANGE
Target $27
WELS
Market Perform
Mallinckrodt investor worries 'worthy of concern,' says Wells Fargo
Wells Fargo analyst David Maris attrubites the 7% selloff yesterday in shares of Mallinckrodt to investors recognizing that the spin-off process could take at least six months and the proceeds previously expected from a sale will now come in the form of levering the spin with debt. Furthering pressing the shares could the realiztioin that the company's opioid and environmental liabilities may not have been fully appreciated, Maris tells investors in a research note partially titled "Questions, But A Reasonable Alternative." The fact that the generics business now has to be consolidated after being reported as a discontinued operation, only to be taken out again when the spin is completed is also challenging for some investors, Maris writes. The analyst, while admitting Mallinckrodt's current cash flow is "very appealing," acknowledges that the re-consolidation and then spin of the generics unit, pending competition of Inomax in 2019, and investor worries about Acthar is "worthy of concern." He maintains a Market Perform rating on Mallinckrodt shares with a $27 price target.
12/17/18
MZHO
12/17/18
NO CHANGE
Target $22
MZHO
Neutral
Mallinckrodt price target lowered to $22 from $29 at Mizuho
Mizuho analyst Irina Koffler lowered her price target for Mallinckrodt to $22 while presenting an initial view of how to value the two separate companies. The analyst reduced estimates for Acthar and took a more "conservative stance" on Amitiza's long-term outlook. She also penalized the spin company $2 per share for estimated opioid liability. Koffler ascribes $16 per share to the branded business and $6 to the spin company. She reiterates a Neutral rating on Mallinckrodt.
MGEN Miragen Therapeutics
$3.40

-0.12 (-3.41%)

12/31/18
RILY
12/31/18
INITIATION
Target $18.5
RILY
Buy
Miragen Therapeutics resumed with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico resumed coverage of Miragen Therapeutics and kept his firm's Buy rating and $18.50 price target on the shares.
01/04/19
BARD
01/04/19
INITIATION
Target $10
BARD
Outperform
Miragen Therapeutics initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Miragen Therapeutics with an Outperform rating, citing its near cash valuation, potential for its drug candidate in mycosis fungoides, and its undervalued MicroRNA platform. Kumar has a $10 price target on Miragen Therapeutics shares.
03/29/18
JEFF
03/29/18
INITIATION
Target $14
JEFF
Buy
Miragen Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Eun Yang started Miragen Therapeutics with a Buy rating and $14 price target. The analyst believes the company has a leading position in microRNA therapy and thinks early clinical data could expand the "relatively inexpensive" valuation.
07/09/18
OPCO
07/09/18
NO CHANGE
Target $19
OPCO
Outperform
Miragen Therapeutics price target raised to $19 from $13 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target fro Miragen Therapeutics to $19 from $13 to account for an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
SPPI Spectrum
$11.07

0.195 (1.79%)

12/20/18
HCWC
12/20/18
NO CHANGE
Target $40
HCWC
Buy
Spectrum selloff yesterday a buying opportunity, says H.C. Wainwright
H.C. Wainwright analyst Edward White views yesterday's weakness in shares of Spectrum Pharmaceuticals as a "good buying opportunity." The analyst points out that Breakthrough Therapy Designation is given to drugs intended to treat a serious condition that may demonstrate substantial improvement over current treatment, with "substantial" being a subjective FDA judgment. While not getting the BTD for poziotinib is disappointing, this should not change the timeline for the Biologics License Application submission or ultimately the possible approval of poziotinib, White tells investors in a research note. He keeps a Buy rating on Spectrum with a $40 price target.
12/20/18
JEFF
12/20/18
NO CHANGE
Target $25
JEFF
Buy
Spectrum 34% selloff today 'clearly overdone,' says Jefferies
Jefferies analyst Roger Song is a "bit surprised" the FDA did not grant Breakthrough Therapy Designation to Spectrum Pharmaceuticals' poziotinib given the drug's "impressive" overall response rate and durability versus current options. However, the company is confident that the planned accelerated approval pathway remains unchanged, Song tells investors in a research note. And the analyst continues to believe an ORR of 25%-30% could support an approval. The after-market selloff of 34% is "clearly overdone" as pivotal data could emerge within 6-12 months followed by a potential first-line indication approval, says the analyst. He keeps a Buy rating on Spectrum with a $25 price target. The stock in premarket trading is down $3.64 to $6.80.
12/20/18
RILY
12/20/18
NO CHANGE
Target $21
RILY
Buy
Spectrum price target lowered to $21 from $29 at B. Riley FBR
B. Riley FBR analyst David Buck lowered his price target for Spectrum Pharmaceuticals to $21 after the FDA denied Breakthrough Therapy Designation for poziotinib. The analyst keeps a Buy rating on the shares.
12/27/18
HCWC
12/27/18
NO CHANGE
Target $40
HCWC
Buy
H.C. Wainwright confident Spectrum BLA will be accepted and approved
After Spectrum Pharmaceuticals announced that it has submitted its Biologics License Application, or BLA, to the FDA for Rolontis, H.C. Wainwright analyst Edward White noted that the company had previously said it planned for a BLA filing by year end. White has confidence the BLA will be accepted and approved, pointing to the strength of the data and the fact it was conducted under a SPA, he tells investors. White keeps a Buy rating and $40 price target on Spectrum shares.

TODAY'S FREE FLY STORIES

02:50
01/22/19
01/22
02:50
01/22/19
02:50
General news
FX Update: The Dollar and Yen have traded firmer »

FX Update: The Dollar…

WOLWF

Woolworths Group

$0.00

(0.00%)

18:51
01/21/19
01/21
18:51
01/21/19
18:51
Downgrade
Woolworths Group rating change at Citi »

Woolworths Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLESY

Lendlease Group

$0.00

(0.00%)

18:48
01/21/19
01/21
18:48
01/21/19
18:48
Upgrade
Lendlease Group rating change at Citi »

Lendlease Group upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$41.41

0.99 (2.45%)

17:56
01/21/19
01/21
17:56
01/21/19
17:56
Earnings
Enterprise Financial reports Q4 EPS $1.02, consensus 95c »

Reports Q4 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FB

Facebook

$150.01

1.77 (1.19%)

16:36
01/21/19
01/21
16:36
01/21/19
16:36
Periodicals
Facebook planning to add 1,000 jobs in Ireland by year-end, Reuters says »

Facebook will hire an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

FB

Facebook

$150.01

1.77 (1.19%)

16:33
01/21/19
01/21
16:33
01/21/19
16:33
Periodicals
Facebook's WhatsApp limits users to five text forwards, Reuters reports »

Facebook's WhatsApp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

ENB

Enbridge

$36.10

0.425 (1.19%)

16:28
01/21/19
01/21
16:28
01/21/19
16:28
Periodicals
Enbridge gas pipeline explosion creates fireball in Ohio, Reuters says »

An explosion of an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIN

Linde plc

$160.76

3.48 (2.21%)

16:25
01/21/19
01/21
16:25
01/21/19
16:25
Periodicals
Linde Plc to launch $6B share buyback scheme, Reuters says »

Linde Plc said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

HENKY

Henkel

$0.00

(0.00%)

16:01
01/21/19
01/21
16:01
01/21/19
16:01
Downgrade
Henkel rating change at Goldman Sachs »

Henkel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAG

Conagra Brands

$21.58

0.34 (1.60%)

14:06
01/21/19
01/21
14:06
01/21/19
14:06
Hot Stocks
Conagra exploring alternatives for Italian-based frozen pasta business »

Conagra Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

13:15
01/21/19
01/21
13:15
01/21/19
13:15
General news
IMF trimmed global growth amid "no-deal" Brexit and trade war concerns »

IMF trimmed global growth…

UQM

UQM Technologies

$1.10

0.05 (4.76%)

13:05
01/21/19
01/21
13:05
01/21/19
13:05
Hot Stocks
UQM Technologies acquired by Danfoss Power Solutions for $1.71 per share »

UQM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$41.50

-0.54 (-1.28%)

12:37
01/21/19
01/21
12:37
01/21/19
12:37
Hot Stocks
Sanofi granted U.K. marketing authorization for TIV High Dose »

U.K. marketing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

RTN

Raytheon

$165.11

2.285 (1.40%)

12:33
01/21/19
01/21
12:33
01/21/19
12:33
Hot Stocks
Raytheon awarded $24.36M order for F/A-18 aircraft system repair »

Raytheon said it was a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBCP

Independent Bank

$22.80

-0.11 (-0.48%)

11:26
01/21/19
01/21
11:26
01/21/19
11:26
Hot Stocks
Independent Bank boosts quarterly dividend by 20% to 18c »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

11:25
01/21/19
01/21
11:25
01/21/19
11:25
General news
FX Update: The dollar majors have been directionally challenged »

FX Update: The dollar…

EDIT

Editas Medicine

$26.16

-0.01 (-0.04%)

11:25
01/21/19
01/21
11:25
01/21/19
11:25
Hot Stocks
Editas Medicine announces publication of EDIT-101 data in Nature Medicine »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

, GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

11:23
01/21/19
01/21
11:23
01/21/19
11:23
Hot Stocks
France's National Data Protection Commission fines Google 50M euros »

France's National…

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

LAD

Lithia Motors

$87.13

1.57 (1.84%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
Lithia Motors to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 13

    Feb

  • 14

    Mar

CYDY

CytoDyn

$0.00

(0.00%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

ABT

Abbott

$71.43

0.9 (1.28%)

09:50
01/21/19
01/21
09:50
01/21/19
09:50
Hot Stocks
Abbott announces FDA approval of TactiCath Contact Force Ablation Catheter »

Abbott announced FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Jan

SFUN

Fang Holdings

$1.88

-0.01 (-0.53%)

09:48
01/21/19
01/21
09:48
01/21/19
09:48
Hot Stocks
Fang announces management changes, proposed China Index spin-off »

Fang Holdings announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TS

Tenaris

$24.32

0.64 (2.70%)

09:45
01/21/19
01/21
09:45
01/21/19
09:45
Hot Stocks
Tenaris closes acquisition of 47.79% of Saudi Steel Pipe shares »

Tenaris S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$14.17

-0.31 (-2.14%)

09:42
01/21/19
01/21
09:42
01/21/19
09:42
Hot Stocks
Pan American reports 2018 silver production 24.8M ounces »

Pan American Silver Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWS

Crown Crafts

$5.68

(0.00%)

09:38
01/21/19
01/21
09:38
01/21/19
09:38
Hot Stocks
Crown Crafts announces retirement of NoJo Baby & Kids CEO »

Crown Crafts (CRWS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.